Medicare Drug Price Negotiation Not A Major Threat To Pharma – Even If It Passes
Executive Summary
Biopharma analysts discuss the likely impact of the drug pricing reform provisions in the Build Back Better legislation, which has hit a roadblock created by Democratic Senator Joe Manchin of West Virginia.
You may also be interested in...
Insulin Copay Bill Advances In What Could Be US Senate Democrats Last Gasp For Price Reform
Though popular, the proposal to cap insulin copays is a relatively minor part of the drug pricing reform package included in the stalled Build Back Better Act. But it may represent Democrats’ best chance of passing any drug pricing-related legislation while they still hold majorities in Congress.
Tweaks To CBO Model May Add Another Hurdle To Congressional Drug Pricing Reform Effort
New model suggests extra hit for accelerated approval drugs. But despite Congress and President Biden looking toward a scaled-backed version of the Build Back Better reconciliation package, many health care politics experts believe drug price negotiation will make it into law this year.
Who Needs Negotiation? US Rx Prices Are Falling – Thanks To Generics
A Congressional Budget Office review of prescription drug pricing trends over the past decade shows a surprising fact: the average costs per prescription in the US is falling. That probably won’t change the political debate over drug prices – but maybe it should.